28 Stocks Moving In Friday's Mid-Day Session

Gainers

• ChemoCentryx, Inc. CCXI shares climbed 60.8% to $31.51. The FDA approved ChemoCentryx’s Tavneos (avacopan) as an adjunctive treatment for anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis or ANCA vasculitis).
• Renren Inc. RENN jumped 40.9% to $23.40. Renren, last month, named Chris Palmer as its Chief Financial Officer.
• ReShape Lifesciences Inc. RSLS shares climbed 28.2% to $3.18. Maxim Group initiated coverage on Reshape Lifesciences with a Buy rating and announced a price target of $8.
• Camber Energy, Inc.. CEI jumped 26.5% to $2.2510 after jumping around 96% on Thursday.
• Huadi International Group Co., Ltd. HUDI gained 17.7% to $3.73.
• Altisource Portfolio Solutions S.A. ASPS surged 16.6% to $13.70. The company recently agreed to sell Pointillist subsidiary for $150 million.
• Aehr Test Systems AEHR gained 14.4% to $19.05. Craig-Hallum raised the price target on Aehr Test Systems to $31 from $12, implying an 86.1% upside, and reiterated a Buy.
• Repare Therapeutics Inc. RPTX jumped 13.5% to $24.85. Repare Therapeutics issued statement regarding inadvertent issuance of Phase 1/2 TRESR RP-3500 clinical trial abstract by AACR-NCI-EORTC Virtual International Conference.
• DatChat, Inc. DATS shares rose 11.4% to $8.96 after gaining over 9% on Thursday.
• Cue Health Inc. HLTH gained 9.4% to $11.82.
• Momentive Global Inc. MNTV rose 9.3% to $23.64. Momentive Global is weighing options, including a potential sale after receiving takeover interest, Bloomberg reported.
• eFFECTOR Therapeutics, Inc. EFTR rose 9.1% to $12.52 after the company, in collaboration with investigators at Baylor College of Medicine, announced the presentation of new data for zotatifin in animal models of triple-negative breast cancer at the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
• Sundial Growers Inc. SNDL rose 8% to $0.70 after the company announced plans to acquire Alcanna for total consideration of approximately $346 million.
• Immuron Limited IMRN rose 5.7% to $3.72 as the company announced a recent publication of antiviral data from the IMM-124E preclinical and Phase 1/2a trials.

Check out these big penny stock gainers and losers

Losers

• Macquarie Infrastructure Corporation MIC shares fell 91.1% to $3.58 .
• Allogene Therapeutics, Inc. ALLO shares dipped 43.3% to $13.79 after the company reported the FDA placed a hold on the company's AlloCAR T clinical trials.
• Agile Therapeutics, Inc. AGRX shares fell 29.5% to $0.6645 after the company announced an offering of common stock and warrants.
• Cellectis S.A. CLLS fell 19% to $9.74. Baird downgraded Cellectis from Outperform to Neutral and lowered the price target from $39 to $10.
• Nkarta, Inc. NKTX dipped 13.7% to $21.57. Nkarta updated guidance on initial data readout of Phase 1 trial of NKX101 in relapsed or refractory acute myeloid leukemia or higher-risk myelodysplastic syndromes.
• Caribou Biosciences, Inc. CRBU dropped 11.7% to $19.95.
• Blue Apron Holdings, Inc. APRN fell 10% to $7.08.
• Omeros Corporation OMER dropped 9.9% to $6.70. JP Morgan downgraded Omeros from Neutral to Underweight.
• Cidara Therapeutics, Inc. CDTX fell 9.6% to $1.69 after the company priced 14.8 million share offering at $1.55 per share.
• Kiromic BioPharma, Inc. KRBP dropped 9.2% to $1.97. Kiromic BioPharma recently named Daniel Clark as interim Chief Financial Officer.
• MaxCyte, Inc. MXCT fell 8.4% to $9.81.
• Sharecare, Inc. SHCR dipped 7.7% to $7.68.
• Lucira Health, Inc. LHDX dipped 7.6% to $6.10. Lucira Health issued a statement on recall of FLOQSwabs by its Italian partner, Copan Italia.
• CareMax, Inc. CMAX dropped 7.2% to $8.18.